PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT

• Francesco Zaja,
• Hanny Al-Samkari,
• Marc Michel,
• Waleed Ghanima,
• Nichola Cooper,
• Raymond Wong,
• Wilma Barcellini,
• Fengkui Zhang,
• Emerenziana Marturano,
• Severine Peyrard,
• Adam Cuker

Affiliations

Francesco Zaja

1 DSM, University of Trieste and Department of Hematology, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy

Hanny Al-Samkari

2 Harvard Medical School, Massachusetts General Hospital, Division of Hematology Oncology, Boston, MA, United States

Marc Michel

3 Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Department of Internal Medicine, Créteil, France

Waleed Ghanima

4 Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Nichola Cooper

5 Imperial College London, Department of Inflammation and Immunity, London, United Kingdom

Raymond Wong

6 The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Shatin, Hong Kong

Wilma Barcellini

7 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Fengkui Zhang

8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Emerenziana Marturano

9 Novartis, Basel, Switzerland

Severine Peyrard

10 Novartis, Paris, France

Adam Cuker

11 Perelman School of Medicine, University of Pennsylvania, Department of Medicine and Department of Pathology and Laboratory Medicine, Philadelphia, PA, United States